An Historic Perspective of Proteasome Inhibition

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 196-206

  Esseltine, Dixie Lee ^a   Mulligan, George ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; ALDEHYDE; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IXAZOMIB CITRATE; KETONE; LACTONE; MELPHALAN; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SULFONE DERIVATIVE; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LUNG CANCER; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN TARGETING; QUALITY CONTROL; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOLOGIC NEOPLASMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITIN;

EID: 84862667721     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.009     Document Type: Article

References (115)

1. Pajic M., Scarlett C.J., Chang D.K., Sutherland R.L., Biankin A.V. Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet 2011, 130:93-101.
2. Cavo M., Rajkumar S.V., Palumbo A., et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011, 117:6063-6073.
3. Ludwig H., Beksac M., Blade J., et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist 2011, 16:388-403.
4. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
5. Gertz M.A. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011, 86:180-186.
6. Goy A., Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2010, 80:69-86.
7. Leonard J.P., Martin P. Novel agents for follicular lymphoma. Hematology Am Soc Hematol Educ Program 2010, 2010:259-264.
8. Wagner S.A., Beli P., Weinert B.T., et al. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics 2011, 10. M111.013284.
9. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005, 12:1178-1190.
10. Goldberg A.L., Dice J.F. Intracellular protein degradation in mammalian and bacterial cells. Annu Rev Biochem 1974, 43:835-869.
11. Hershko A., Ciechanover A., Heller H., Haas A.L., Rose I.A. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A 1980, 77:1783-1786.
12. Hershko A., Ciechanover A., Rose I.A. Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem 1981, 256:1525-1528.
13. Hough R., Pratt G., Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem 1987, 262:8303-8313.
14. Borissenko L., Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007, 107:687-717.
15. Ciechanover A., Elias S., Heller H., Hershko A. "Covalent affinity" purification of ubiquitin-activating enzyme. J Biol Chem 1982, 257:2537-2542.
16. Hershko A., Heller H., Elias S., Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 1983, 258:8206-8214.
17. Bedford L., Lowe J., Dick L.R., Mayer R.J., Brownell J.E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011, 10:29-46.
18. Goldberg A.L., Stein R., Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995, 2:503-508.
19. Schwartz A.L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999, 50:57-74.
20. Anelli T., Sitia R. Protein quality control in the early secretory pathway. EMBO J 2008, 27:315-327.
21. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
22. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
23. Reddy N., Czuczman M.S. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol 2010, 21:1756-1764.
24. Goy A., Bernstein S.H., McDonald A., et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010, 51:1269-1277.
25. Mulligan G., Mitsiades C., Bryant B., et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109:3177-3188.
26. Coiffier B., Osmanov E.A., Hong X., et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011, 12:773-784.
27. Coiffier B., Li W., Henitz E.D., et al. Identification of patient subgroups demonstrating longer progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in patients with relapsed or refractory follicular lymphoma (FL): biomarker analyses of the phase 3 LYM3001 study. Blood 2011, 118:122. (abstract 265).
28. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006, 5:596-613.
29. Schulman B.A., Harper J.W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009, 10:319-331.
30. Vinitsky A., Cardozo C., Sepp-Lorenzino L., Michaud C., Orlowski M. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 1994, 269:29860-29866.
31. Iqbal M., Chatterjee S., Kauer J.C., et al. Potent inhibitors of proteasome. J Med Chem 1995, 38:2276-2277.
32. Rock K.L., Gramm C., Rothstein L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
33. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758.
34. Myung J., Kim K.B., Crews C.M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001, 21:245-273.
35. Orlowski R.Z., Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14:1649-1657.
36. Rolfe M., Chiu M.I., Pagano M. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med (Berl) 1997, 75:5-17.
37. Delic J., Masdehors P., Omura S., et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998, 77:1103-1107.
38. Orlowski R.Z., Eswara J.R., Lafond-Walker A., et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998, 58:4342-4348.
39. Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996, 335:1897-1905.
40. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
41. Grisham M.B., Palombella V.J., Elliott P.J., et al. Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 1999, 300:345-363.
42. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
43. Goldberg A.L., Rock K. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat Med 2002, 8:338-340.
44. Adams J., Behnke M., Chen S., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998, 8:333-338.
45. Teicher B.A., Ara G., Herbst R., Palombella V.J., Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5:2638-2645.
46. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
47. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
48. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
49. Abukhdeir A.M., Park B.H. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008, 10:e19.
50. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
51. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002, 8:S49-S54.
52. Boccadoro M., Morgan G., Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005, 5:18.
53. Soucy T.A., Smith P.G., Milhollen M.A., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
54. Soucy T.A., Dick L.R., Smith P.G., Milhollen M.A., Brownell J.E. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010, 1:708-716.
55. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107:241-246.
56. Bours V., Dejardin E., Goujon-Letawe F., Merville M.P., Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994, 47:145-149.
57. Sharma H.W., Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res 1996, 16:589-596.
58. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647.
59. Chaturvedi M.M., Sung B., Yadav V.R., Kannappan R., Aggarwal B.B. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011, 30:1615-1630.
60. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
61. Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. Blood 2009, 113:6069-6076.
62. Ruan J., Martin P., Furman R.R., et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29:690-697.
63. Leonard J.P., Reeves J., Ferhanoglu B., et al. PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification. J Clin Oncol 2011, 29. TPS226 (abstract TPS226).
64. Wright J.J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010, 16:4094-4104.
65. Mitsiades C.S., Hayden P.J., Anderson K.C., Richardson P.G. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007, 20:797-816.
66. Lightcap E.S., McCormack T.A., Pien C.S., et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000, 46:673-683.
67. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002, 8:2505-2511.
68. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
69. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
70. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
71. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
72. Reece D.E., Hegenbart U., Sanchorawala V., et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011, 118:865-873.
73. Treon S.P., Hunter Z.R., Matous J., et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG trial 03-248. Clin Cancer Res 2007, 13:3320-3325.
74. Lonial S., Waller E.K., Richardson P.G., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106:3777-3784.
75. Lonial S., Richardson P.G., San M.J., et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008, 143:222-229.
76. Fitzgerald M., Fraser C., Webb I., et al. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol Blood Marrow Transplant 2003, 9:121.
77. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114:1729-1735.
78. Oakervee H., Popat R., Cavenagh J.D. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma 2007, 48:1910-1921.
79. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
80. Richardson P.G., Delforge M., Beksac M., et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012, 26:595-608.
81. Xue W., Meylan E., Oliver T.G., et al. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 2011, 1:236-247.
82. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
83. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
84. San Miguel J.F., Schlag R., Khuageva N.K., et al. Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial. Blood 2011, 118:221-222. (abstract 476).
85. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
86. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28:4621-4629.
87. Dimopoulos M., Kyle R., Fermand J.P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4705.
88. Munshi N.C., Anderson K.C., Bergsagel P.L., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
89. Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
90. Broyl A., Corthals S.L., Jongen J.L., et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, 11:1057-1065.
91. Corthals S.L., Kuiper R., Johnson D.C., et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011, 96:1728-1732.
92. Dimopoulos M.A., Richardson P.G., Schlag R., et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009, 27:6086-6093.
93. San-Miguel J.F., Richardson P.G., Sonneveld P., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
94. Delforge M., Terpos E., Richardson P.G., et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011, 86:372-384.
95. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010, 15:243-249.
96. Kupperman E., Lee E.C., Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010, 70:1970-1980.
97. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
98. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
99. Zhu Y.X., Tiedemann R., Shi C.X., et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 2011, 117:3847-3857.
100. Escobar M., Velez M., Belalcazar A., Santos E.S., Raez L.E. The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol 2011, 2011:806506.
101. Conrad C., Podolsky M.J., Cusack J.C. Antiproteasomal agents in rectal cancer. Anticancer Drugs 2011, 22:341-350.
102. Sato K., Rajendra E., Ohta T. The UPS: a promising target for breast cancer treatment. BMC Biochem 2008, 9(Suppl 1):S2.
103. Kuhn D.J., Hunsucker S.A., Chen Q., et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113:4667-4676.
104. Rock K.L., York I.A., Saric T., Goldberg A.L. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002, 80:1-70.
105. Bodas M., Vij N. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 2010, 9:346-356.
106. Herrmann J., Ciechanover A., Lerman L.O., Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res 2004, 61:11-21.
107. Lehman N.L. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009, 118:329-347.
108. Petroski M.D. The ubiquitin system, disease, and drug discovery. BMC Biochem 2008, 9(Suppl 1):S7.
109. Ganoth D., Leshinsky E., Eytan E., Hershko A. A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation. J Biol Chem 1988, 263:12412-12419.
110. Ciechanover A., Heller H., Katz-Etzion R., Hershko A. Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad Sci U S A 1981, 78:761-765.
111. Orlowski M., Wilk S. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides. Biochem Biophys Res Commun 1981, 101:814-822.
112. Wilk S., Orlowski M. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J Neurochem 1983, 40:842-849.
113. Arrigo A.P., Tanaka K., Goldberg A.L., Welch W.J. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1988, 331:192-194.
114. Eytan E., Ganoth D., Armon T., Hershko A. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc Natl Acad Sci U S A 1989, 86:7751-7755.
115. Falkenburg P.E., Haass C., Kloetzel P.M., et al. Drosophila small cytoplasmic 19S ribonucleoprotein is homologous to the rat multicatalytic proteinase. Nature 1988, 331:190-192.